DE69841806D1 - Ligandenbindungsstelle von rage und deren verwendungen - Google Patents
Ligandenbindungsstelle von rage und deren verwendungenInfo
- Publication number
- DE69841806D1 DE69841806D1 DE69841806T DE69841806T DE69841806D1 DE 69841806 D1 DE69841806 D1 DE 69841806D1 DE 69841806 T DE69841806 T DE 69841806T DE 69841806 T DE69841806 T DE 69841806T DE 69841806 D1 DE69841806 D1 DE 69841806D1
- Authority
- DE
- Germany
- Prior art keywords
- peptide
- amino acid
- acid sequence
- present
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 9
- 102000005622 Receptor for Advanced Glycation End Products Human genes 0.000 abstract 6
- 108010045108 Receptor for Advanced Glycation End Products Proteins 0.000 abstract 6
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 5
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 230000003993 interaction Effects 0.000 abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/948,131 US6555651B2 (en) | 1997-10-09 | 1997-10-09 | Ligand binding site of rage and uses thereof |
PCT/US1998/021346 WO1999018987A1 (en) | 1997-10-09 | 1998-10-09 | Ligand binding site of rage and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69841806D1 true DE69841806D1 (de) | 2010-09-16 |
Family
ID=25487337
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69841806T Expired - Lifetime DE69841806D1 (de) | 1997-10-09 | 1998-10-09 | Ligandenbindungsstelle von rage und deren verwendungen |
Country Status (12)
Country | Link |
---|---|
US (1) | US6555651B2 (de) |
EP (2) | EP2343316A1 (de) |
JP (2) | JP2001519401A (de) |
AT (1) | ATE476192T1 (de) |
AU (1) | AU9795898A (de) |
CY (1) | CY1110884T1 (de) |
DE (1) | DE69841806D1 (de) |
DK (1) | DK1023080T3 (de) |
ES (1) | ES2351876T3 (de) |
HK (1) | HK1031100A1 (de) |
PT (1) | PT1023080E (de) |
WO (1) | WO1999018987A1 (de) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6555651B2 (en) * | 1997-10-09 | 2003-04-29 | The Trustees Of Columbia University In The City Of New York | Ligand binding site of rage and uses thereof |
US7258857B2 (en) * | 1996-11-22 | 2007-08-21 | The Trustees Of Columbia University In The City Of New York | Rage-related methods for treating inflammation |
US6790443B2 (en) * | 1996-11-22 | 2004-09-14 | The Trustees Of Columbia University In The City Of New York | Method for treating symptoms of diabetes |
US7081241B1 (en) * | 1998-10-06 | 2006-07-25 | The Trustees Of Columbia University In The City Of New York | Extracellular rage binding protein (EN-RAGE) and uses thereof |
US7101838B2 (en) * | 1997-08-05 | 2006-09-05 | The Trustees Of Columbia University In The City Of New York | Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts |
US6465422B1 (en) * | 1998-04-17 | 2002-10-15 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting tumor invasion or spreading in a subject |
EP1121454B1 (de) * | 1998-10-06 | 2007-11-14 | The Trustees of Columbia University in the City of New York | Extrazelluläres, neues rage-bindendes protein (en-rage) und dessen verwendungen |
CA2382095A1 (en) * | 1999-08-13 | 2001-02-22 | The Trustees Of Columbia University In The City Of New York | Methods of inhibiting binding of .beta.-sheet fibril to rage and consequences thereof |
US20050170382A1 (en) * | 1999-10-06 | 2005-08-04 | The Trustees Of Columbia University In The City Of New York. | RAGE-related compositions |
US6613801B2 (en) | 2000-05-30 | 2003-09-02 | Transtech Pharma, Inc. | Method for the synthesis of compounds of formula I and their uses thereof |
US6908741B1 (en) * | 2000-05-30 | 2005-06-21 | Transtech Pharma, Inc. | Methods to identify compounds that modulate RAGE |
EP1724589A3 (de) * | 2000-05-30 | 2007-04-25 | TransTech Pharma Inc. | Verfahren zur identifizierung von rage-modulierenden verbindungen |
US7919670B1 (en) | 2000-08-14 | 2011-04-05 | The Trustees Of Columbia University In The City Of New York | Transgenic mice over-expressing receptor for advanced glycation endproduct (RAGE) in brain and uses thereof |
PE20020394A1 (es) | 2000-08-18 | 2002-06-21 | Agouron Pharma | Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2 |
US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
US7723303B2 (en) * | 2000-08-24 | 2010-05-25 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
US7199102B2 (en) * | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
US7148197B2 (en) * | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
AU2002213192A1 (en) * | 2000-10-13 | 2002-04-22 | The Trustees Of Columbia University In The City Of New York | A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury |
JP2004523565A (ja) | 2001-03-05 | 2004-08-05 | トランス テック ファーマ,インコーポレイテッド | 治療因子としてのベンゾイミダゾール誘導体 |
CN1494425B (zh) | 2001-03-05 | 2011-12-07 | 特兰斯泰克制药公司 | 用作治疗剂的羧酰胺衍生物 |
CN101597262A (zh) | 2002-03-05 | 2009-12-09 | 特兰斯泰克制药公司 | 抑制配体与高级糖化终产物受体相互作用的单和双环吡咯衍生物 |
WO2004016229A2 (en) * | 2002-08-16 | 2004-02-26 | Wyeth | Compositions and methods for treating rage-associated disorders |
WO2004100890A2 (en) * | 2003-05-09 | 2004-11-25 | The Trustees Of Columbia University In The City Of New York | Rage g82s-related methods and compositions for treating inflammatory disorders |
WO2006012415A2 (en) * | 2004-07-20 | 2006-02-02 | Critical Therapeutics, Inc. | Rage protein derivatives |
WO2006017647A1 (en) * | 2004-08-03 | 2006-02-16 | Transtech Pharma, Inc. | Rage fusion proteins and methods of use |
EP1776459A1 (de) * | 2004-08-03 | 2007-04-25 | Transtech Pharma, Inc. | Rage-fusionsproteine und verfahren zu ihrer verwendung |
CA2580501A1 (en) * | 2004-09-16 | 2006-03-30 | The Regents Of The University Of California | G-type peptides and other agents to ameliorate atherosclerosis and other pathologies |
US20060084145A1 (en) * | 2004-09-27 | 2006-04-20 | Anderson Glenn M | sRAGE mimetibody, compositions, methods and uses |
EP1827472A4 (de) | 2004-12-06 | 2012-09-05 | Univ California | Verfahren zur verbesserung der struktur und funktion von arteriolen |
EP1838339A2 (de) * | 2005-01-18 | 2007-10-03 | Abbott GmbH & Co. KG | Ager-peptide und deren verwendung |
US9291621B2 (en) * | 2005-01-18 | 2016-03-22 | AbbVie Deutschland GmbH & Co. KG | AGER-peptides and use thereof |
CA2601630A1 (en) * | 2005-03-17 | 2006-09-21 | The Trustees Of Columbia University In The City Of New York | Rage/diaphanous interaction and related compositions and methods |
US20080293639A1 (en) * | 2005-04-29 | 2008-11-27 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
MX2007013430A (es) * | 2005-04-29 | 2008-03-19 | Univ California | Peptidos y peptidos mimeticos para tratar patologias caracterizadas por una respuesta inflamatoria. |
US20080207499A1 (en) * | 2005-06-29 | 2008-08-28 | Gaetano Barile | Rage-related methods for treating and preventing diabetic retinopathy |
JP5314428B2 (ja) * | 2005-12-23 | 2013-10-16 | ジーコデール システムズ アクチボラゲット | 測位用パターン |
AU2007215503A1 (en) * | 2006-02-09 | 2007-08-23 | Transtech Pharma, Inc. | Rage fusion proteins and methods of use |
EP2021474A2 (de) | 2006-05-05 | 2009-02-11 | Transtech Pharma, Inc. | Rage-fusionsproteine, formulierungen daraus und verfahren zu ihrer verwendung |
WO2008100470A2 (en) * | 2007-02-15 | 2008-08-21 | Transtech Pharma, Inc. | Rage - immunoglobulin fusion proteins |
US20100254983A1 (en) * | 2007-06-07 | 2010-10-07 | Ann Marie Schmidt | Uses of rage antagonists for treating obesity and related diseases |
PL2158210T3 (pl) | 2007-06-14 | 2016-08-31 | Galactica Pharmaceuticals Inc | Białka fuzyjne RAGE |
CA2697957A1 (en) | 2007-08-28 | 2009-03-12 | Uab Research Foundation | Synthetic apolipoprotein e mimicking polypeptides and methods of use |
DK2682400T5 (da) | 2007-08-28 | 2017-11-27 | Uab Research Foundation | Syntetiske apolipoprotein E-efterlignende polypeptider og fremgangsmåder til anvendelse |
RU2011142230A (ru) | 2009-04-20 | 2013-05-27 | Пфайзер Инк. | Контроль гликозилирования белка и композиции и способы, касающиеся этого |
TWI517850B (zh) | 2009-09-30 | 2016-01-21 | Vtv治療有限責任公司 | 經取代之咪唑衍生物及其使用方法 |
US8431575B2 (en) | 2010-02-18 | 2013-04-30 | Transtech Pharma, Inc. | Phenyl-heteroaryl derivatives and methods of use thereof |
JP5999542B2 (ja) * | 2010-11-18 | 2016-09-28 | 国立研究開発法人農業・食品産業技術総合研究機構 | リガンド様活性を有する分子の検出方法 |
US9244074B2 (en) | 2011-06-07 | 2016-01-26 | University Of Hawaii | Biomarker of asbestos exposure and mesothelioma |
US9561274B2 (en) | 2011-06-07 | 2017-02-07 | University Of Hawaii | Treatment and prevention of cancer with HMGB1 antagonists |
US9717710B2 (en) | 2012-10-05 | 2017-08-01 | Vtv Therapeutics Llc | Treatment of mild and moderate Alzheimer's disease |
KR101595630B1 (ko) * | 2013-01-18 | 2016-02-18 | 성균관대학교산학협력단 | Rage 단백질-베타아밀로이드 상호작용 억제제, 및 이를 유효성분으로 함유하는 베타아밀로이드 집적 관련 질환의 예방 또는 치료용 약학적 조성물 |
WO2016018665A1 (en) | 2014-07-31 | 2016-02-04 | Uab Research Foundation | Apoe mimetic peptides and higher potency to clear plasma cholesterol |
WO2019190823A1 (en) | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine |
WO2019190822A1 (en) | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine |
WO2020076668A1 (en) | 2018-10-10 | 2020-04-16 | Vtv Therapeutics Llc | Metabolites of [3-(4-{2-butyl-l-[4-(4-chloro-phenoxy)-phenyl]-lh-imidazol-4-yl } -phen ox y)-prop yl] -diethyl-amine |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
US5585344A (en) | 1984-03-19 | 1996-12-17 | The Rockefeller University | Liver-derived receptors for advanced glycosylation endproducts and uses thereof |
AU692237B2 (en) | 1994-02-03 | 1998-06-04 | Picower Institute For Medical Research, The | Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis |
US6184205B1 (en) * | 1994-07-22 | 2001-02-06 | University Of North Carolina At Chapel Hill | GRB2 SH3 binding peptides and methods of isolating and using same |
EP0870040A2 (de) * | 1995-12-29 | 1998-10-14 | Chiron Corporation | Genabgabevehikel-zielgerichtete ligande |
WO1997026913A1 (en) | 1996-01-26 | 1997-07-31 | The Trustees Of Columbia University In The City Of New York | A POLYPEPTIDE FROM LUNG EXTRACT WHICH BINDS AMYLOID-β PEPTIDE |
CN1229498C (zh) * | 1996-02-21 | 2005-11-30 | 美国国有卫生与人类服务部 | 重组的核糖核酸酶蛋白质 |
US5864018A (en) * | 1996-04-16 | 1999-01-26 | Schering Aktiengesellschaft | Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor |
AU2696097A (en) | 1996-04-16 | 1997-11-07 | Schering Aktiengesellschaft | Advanced glycosylation end-product receptor peptides and uses therefor |
US5688653A (en) | 1996-06-27 | 1997-11-18 | The Picower Institute For Medical Research | 3-alkylamino-2-hydroxy-4-hydroxymethyl-2-cyclopenten-1-one advanced glycosylation endproducts and methods of use therefor |
US6555651B2 (en) * | 1997-10-09 | 2003-04-29 | The Trustees Of Columbia University In The City Of New York | Ligand binding site of rage and uses thereof |
-
1997
- 1997-10-09 US US08/948,131 patent/US6555651B2/en not_active Expired - Fee Related
-
1998
- 1998-10-09 WO PCT/US1998/021346 patent/WO1999018987A1/en active Application Filing
- 1998-10-09 EP EP10171799A patent/EP2343316A1/de not_active Withdrawn
- 1998-10-09 DK DK98952204.0T patent/DK1023080T3/da active
- 1998-10-09 EP EP98952204A patent/EP1023080B1/de not_active Expired - Lifetime
- 1998-10-09 AT AT98952204T patent/ATE476192T1/de active
- 1998-10-09 JP JP2000515619A patent/JP2001519401A/ja not_active Withdrawn
- 1998-10-09 PT PT98952204T patent/PT1023080E/pt unknown
- 1998-10-09 DE DE69841806T patent/DE69841806D1/de not_active Expired - Lifetime
- 1998-10-09 ES ES98952204T patent/ES2351876T3/es not_active Expired - Lifetime
- 1998-10-09 AU AU97958/98A patent/AU9795898A/en not_active Abandoned
-
2001
- 2001-02-02 HK HK01100756.3A patent/HK1031100A1/xx not_active IP Right Cessation
-
2010
- 2010-01-08 JP JP2010002870A patent/JP2010143932A/ja active Pending
- 2010-11-04 CY CY20101100995T patent/CY1110884T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CY1110884T1 (el) | 2015-06-10 |
EP1023080B1 (de) | 2010-08-04 |
DK1023080T3 (da) | 2010-11-15 |
US20010053357A1 (en) | 2001-12-20 |
HK1031100A1 (en) | 2001-06-01 |
ATE476192T1 (de) | 2010-08-15 |
ES2351876T3 (es) | 2011-02-11 |
JP2010143932A (ja) | 2010-07-01 |
EP2343316A1 (de) | 2011-07-13 |
JP2001519401A (ja) | 2001-10-23 |
US6555651B2 (en) | 2003-04-29 |
PT1023080E (pt) | 2010-10-18 |
WO1999018987A1 (en) | 1999-04-22 |
EP1023080A1 (de) | 2000-08-02 |
EP1023080A4 (de) | 2003-03-19 |
AU9795898A (en) | 1999-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69841806D1 (de) | Ligandenbindungsstelle von rage und deren verwendungen | |
ATE428785T1 (de) | Aktive und inactive cc-chemokinrezeptoren und nukleinsäuremoleküle, die für diesen rezeptor kodieren | |
RU95110871A (ru) | Способы определения нуклеотидной последовательности | |
ES2162132T3 (es) | Polimerasa de adn termoestable procedente de thermoanaerobacter thermohydrosulfuricus y enzimas mutantes, de actividad exonucleasa suprimida asi obtenidos. | |
GB9720054D0 (en) | Biological products | |
WO1999058571A3 (de) | Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung | |
HK1026368A1 (en) | Remedies for lymphocytic tumors. | |
WO1996009386A3 (en) | Allelic variation of the serotonin 5ht2c receptor | |
AR244544A1 (es) | Composicion desodorante. | |
EP1037999A4 (de) | Porphorymonas gingivalis polypeptide und polynukleotide | |
DE69927795D1 (en) | Temperaturstabile dna polymerase aus thermoanaerobacter thermohydrosulfuricus | |
NO972313L (no) | Peptider som er i stand til å binde til GAP-protein-SH3-området, nukleotid-sekvenser som koder for dette samt fremstilling og bruk derav | |
AU8811298A (en) | Novel peptides and polypeptides useful for regenerating the nervous system | |
ATE315577T1 (de) | Neue aminosäuresequenzen, deren kodierende dns, antikörper dagegen und deren verwendungen | |
CO4480058A1 (es) | Genes codificantes y procedimiento de expresion de una nueva enzima: ftalil amidasa | |
WO1996016084A3 (en) | A method of identifying cftr-binding compounds useful for activating chloride conductance in animal cells | |
DE59105231D1 (de) | Klonierung und Überexpression von Glucose-6-Phosphat-Dehydrogenase aus Leuconostoc dextranicus. | |
EP0837074A3 (de) | Biologisch aktives Fibronektin-Fragment als Krebsmetastasehemmstoff | |
GB9226144D0 (en) | Further improvements relating to the radiolabelling of proteins | |
Dianoux et al. | Effects of proteolytic fragmentations on the activity of the mitochondrial natural ATPase inhibitor | |
EP1013665A4 (de) | Neue polypeptide mit wasserkanalaktivität und dna sequenzen | |
EP0911408A3 (de) | DNA kodierend für eine Serin/Threonin Kinase | |
WO2001049714A3 (en) | Nope polypeptides, encoding nucleic acids and methods of use | |
CA2177600A1 (fr) | Sequences d'acides nucleiques regulatrices et utilisations | |
Linder et al. | Separation of human pancreatic carboxypeptidase A isoenzymes by high performance liquid chromatography |